Rheumatoid arthritis: A current view;Artrite reumatoide: uma visão atual

Jornal Brasileiro de Patologia e Medicina Laboratorial

Volumn 47, Issue 5, 2011, Pages 495-503

  Goeldner, Isabela ^a   Skare, Thelma L ^b   De Messias Reason, Iara T ^a   Da Rosa Utiyama, Shirley Ramos ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Faculdade Evangelica de Medicina do Parana   (Brazil)

Author keywords

Auto antibodies; Diagnosis; Rheumatoid arthritis

Indexed keywords

EID: 80155168987     PISSN: 16762444     EISSN: 16784774     Source Type: Journal    
DOI: 10.1590/s1676-24442011000500002     Document Type: Review

References (79)

1. ALAMANOS, Y.; VOULGARI, P. V.; DROSOS, A. A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum, v. 36, p. 182-8, 2006.
2. Albani, S.; Carson, D.A. Etiology and pathogenesis of rheumatoid arthritis. In: Koopman, W. J. Arthritis and allied conditions. A textbook of rheumatology. 13. ed., Baltimore: Williams & Wilkins, 1997, p. 979-92.
3. ALESSANDRI, C. et al. The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis. Clinic Rev Allerg Immunol, v. 34, p. 45-9, 2008.
4. ALETAHA, D. et al. 2010 Rheumatoid arthritis classification criteria. Arthritis Rheum, v. 62, n. 9, p. 2569-81, 2010.
5. ANNE, C. Th17 cells in inflammatory conditions. Rev Diabetic Stud, v. 3, p. 72-5, 2006.
6. ARBUCKLE, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med, v. 349, p. 1526-33, 2003. (Pubitemid 37255038)
7. ARNETT, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, v. 31, p. 315-24, 1988.
8. BALSA, A. et al. Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther, v. 12, n. 2, p. R62, 2010.
9. BUCKLEY, C. D. Science, medicine, and the future: treatment of rheumatoid arthritis. BMJ, v. 315, p. 236-8, 1997. (Pubitemid 27326332)
10. BUREK, C. L.; ROSE, N. R. Autoantibodies. In: COLVIN, R. B.; BHAN, A. K.; McMLUSKEY, R. T. Diagnostic immunopathology. 2. ed. New York: Raven Press, 1995. p. 207-30.
11. CAPPUZZO, K. A. Diagnosis and treatment of early active rheumatoid arthritis. Consult Pharm, v. 23, n. 12, p. 956-61, 2008.
12. CLAVEL, C. et al. Induction of macrophage secretion of TNFá through Fcã receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum, v. 58, n. 3, p. 678-88, 2008. (Pubitemid 351364865)
13. CONSTANTINESCU, F. et al. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care, v. 47, n. 3, p. 350-5, 2009.
14. CRISCIONE, L. G.; St. CLAIR, E. W. Tumor necrosis factoralfa antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol, v.14, p. 204-11, 2002. (Pubitemid 34439081)
15. DE PABLO, P. et al. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol, v. 5, n. 4, p. 218-24, 2009.
16. EGSMOSE, C. et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5-year followup of a prospective double blind placebo controlled study. J Rheumatol, v. 22, p. 2208-13, 1995.
17. EMERY, P. Treatment of rheumatoid arthritis. BMJ, v. 332, n. 7534, p. 152-5, 2006. (Pubitemid 43139408)
18. FABIEN, N. et al. Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study. Clin Rev Allergy Immunol, v. 34, n. 1, p. 40-4, 2008.
19. FELDMANN, M.; BRENNAN, F. M. Rheumatoid arthritis. Cell, v. 85, p. 307-10, 1996. (Pubitemid 26160702)
20. FELSON, D. T. Comparing the prevalence of rheumatic diseases in China with the rest of the world. Arthritis Res Ther, v. 10, n. 1, p. 106, 2008.
21. Ferucci, E. D.; Templin, D. W.; Lanier, A. P. Rheumatoid arthritis in American Indians and Alaska natives: a review of the literature. Semin Arthritis Rheum, v. 34, n. 4, p. 662-7, 2005. (Pubitemid 40193364)
22. FIKE, D. J. Non-organ-specific autoimmune disease. In: SHEEHAN, C. Clin Immunol. 2. ed. Philadelphia: Lippincott, 1997. p. 283-96.
23. FIRESTEIN, G. S. Evolving concepts of rheumatoid arthritis. Nature, v. 5, n. 423, p. 356-61, 2003. (Pubitemid 40852711)
24. GLEISSNER, C. et al. The role of risk factors for periodontal disease in patients with rheumatoid arthritis. Eur J Med Res, v. 3, n. 8, p. 387-92, 1998.
25. GOELDNER, I. et al. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil. Rheumatology (Oxford), v. 49, n. 8, p. 1590-3, 2010.
26. Goodson, N. J.; Farragher, T. M.; Symmons, D. P. Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis. J Rheumatol, v. 35, n. 6, p. 945-9, 2008. (Pubitemid 351813132)
27. GRANT, S. F. et al. The inheritance of rheumatoid arthritis in Iceland. Arthritis Rheum, v. 44, n. 10, p. 2247-54, 2001. (Pubitemid 32977492)
28. HABASH-BSEISO, D. E. et al. Serologic testing in connective tissue diseases. Clin Med Res, v. 3, n. 3, p. 190-3, 2005.
29. HARNEY, S.; WORDSWORTH, B. P. Genetic epidemiology of rheumatoid arthritis. Tissue Antigens, v. 60, n. 6, p. 465-73, 2002. (Pubitemid 36177268)
30. HARTY, L. C.; VEALE, D.J. Irish smokers with rheumatoid arthritis suffer more than their nonsmoking counterparts. J Rheumatol, v. 37, n. 5, p. 1062, 2010.
31. HELLMANN, D. B.; STONE, J. H. Arthritis & musculoskeletal disorders. In: TIERNEY, L. M. et al. Curr Med Diag Treat. ed. New York: McGraw-Hill, 2004. p. 797-825.
32. INBODEM, J. B. The immunopathogenesis of rheumatoid arthritis. Annu Rev Pathol Mech Dis, v. 4, p. 417-34, 2009.
33. IOAN-FACSINAY, A. et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum, v. 58, p. 3000-8, 2008.
34. JASKOWSKI, T. D. et al. Relationship between rheumatoid factor isotypes and IgG anti cyclic citrulinated peptide antibodies. J Rheumatol, v. 37, n. 8, p. 1582-8, 2010.
35. Jorgensen, C. et al. IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications. Clin Exp Rheumatol, v. 14, n. 3, p. 301-4, 1996. (Pubitemid 26290871)
36. KINLOCH, A. et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum, v. 58, n. 8, p. 2287-95, 2008.
37. KLARESKOG, L. et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum, v. 54, n. 1, p. 38-46, 2006. (Pubitemid 43122184)
38. KLARESKOG, L.; WEDREN, S.; ALFREDSSON, L. On the origins of complex immune-mediated disease: the example of rheumatoid arthritis. J Mol Med, v. 87, n. 4, p. 357-62, 2009.
39. KOUMANTAKI, Y. et al. Family history as a risk factor for rheumatoid arthritis: a case-control study. J Rheumatol, v. 24, n. 8, p. 1522-6, 1997. (Pubitemid 27320692)
40. KWOH, C. K. et al. Age, sex, and the familial risk of rheumatoid arthritis. Am J Epidemiol, v. 144, n. 1, p. 15-24, 1996. (Pubitemid 26225283)
41. LEE, D. M.; WEINBLATT, M. E. Rheumatoid arthritis. Lancet, v. 358, p. 903-11, 2001. (Pubitemid 32900579)
42. Lundkvist, J.; Kastang , F.; Kobelt , G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ, v. 8, suppl. 2, p. S49-60, 2008.
43. LUNDSTRÖM, E. et al. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheum, v. 60, n. 6, p. 1597-603, 2009.
44. MacGREGOR, A. J. et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum, v. 43, p. 30-7, 2000. (Pubitemid 30368210)
45. Majithia, V.; Geraci, S. A. Rheumatoid arthritis: diagnosis and management. Am J Med, v. 120, n. 11, p. 936-9, 2007. (Pubitemid 47633476)
46. MAJKA, D. S. et al. Duration of preclinical RA-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis, v. 67, p. 801-7, 2008. (Pubitemid 351829380)
47. MARQUES, J. F. N. et al. Estudo multicêntrico da prevalência da artrite reumatóide do adulto em amostras da população brasileira. Rev Bras Reumatol, v. 33, n. 5, p. 169-73, 1993.
48. MICHOU, L. et al. Prevalence and distribution of autoimmune diseases in 368 rheumatoid arthritis families. J Rheumatol, v. 35, n. 5, p. 1-7, 2008.
49. MIOSSEC, P.; KORN, T.; KUCHROO, V. K. Interleukin-17 and type 17 helper T cells. N Engl J Med, v. 361, p. 888-98, 2009.
50. NELL-DUXNEUNER, V. et al. Autoantibody profiling in patients with very early rheumatoid arthritis-a follow-up study. Ann Rheum Dis, v. 69, n. 1, p. 169-74, 2009.
51. NIELEN, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum, v. 50, n. 2, p. 380-6, 2004. (Pubitemid 38198821)
52. NISHIMURA, K. et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med, v. 146, n. 11, p. 797-808, 2007. (Pubitemid 351650500)
53. OZBALKAN, Z. et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis, v. 212, n. 2, p. 377-82.
54. PADYUKOV, L. et al. A gene-environment interaction between smoking and shared epitope genes in HLADR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum, v. 50, n. 10, p. 3085-92, 2004. (Pubitemid 39371983)
55. PARADOWSKA, A. et al. The function of interleukin 17 in the pathogenesis of rheumatoid arthritis. Arch Immunol Ther Exp, v. 55, n. 5, p. 329-34, 2007.
56. Rantap ää-Dahlqvist, S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum, v. 48, n. 10, p. 2741-9, 2003. (Pubitemid 37280601)
57. Reparon-Schuijt, C. C. et al. Secretion of anti-citrullinecontaining peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum, v. 44, n. 1, p. 41-7, 2001. (Pubitemid 32113116)
58. ROJAS-VILLARRAGA, A. et al. Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. J Autoimmun, v. 32, n. 1, p. 64-9, 2009.
59. SACK, K. E.; FYE, K. H. Doenças reumáticas. In: STITES, D. P.; TERR, A. I.; PARSLOW, T. G. Imunologia médica. ed. Rio de Janeiro: Guanabara Koogan, 2000. p. 353-70.
60. Shinomiya , F. et al. Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period. Mod Rheumatol, v. 18, n. 2, p. 165-9, 2008.
61. SOKKA, T. et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther, v. 11, p. R7, 2009.
62. STAHL, E. A. et al. Genome-wide association study metaanalysis identifies seven new rheumatoid arthritis risk loci. Nat Genet, v. 42, n. 6, p. 508-14, 2010.
63. SUREH, E. Recent advances in rheumatoid arthritis. Post Grad Med J, v. 86, p. 243-250, 2010.
64. SVENDSEN, A. J. et al. Relative importance of genetic effects in rheumatoid arthritis: historical cohort study of Danish nationwide twin population. BMJ, v. 324, n. 7332, p. 264-6, 2002. (Pubitemid 34121835)
65. TAN, R. J. L. et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor Treatment. Ann Rheum Dis, v. 69, n. 6, p. 1029-35, 2010.
66. TEHLIRIAN, C. V.; BATHON, J. M. Rheumatoid arthritis: clinical and laboratory manifestations. In: STONE, J. H.; CROFFORD, L. J.; WHITE, P. H. Primer on the rheumatic diseases. 30. ed. New York: Springer, 2008. p. 114-21.
67. Toussirot , E.; Roudier , J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol, v. 22, n. 5, p. 883-96, 2008.
68. TSAKONAS, E. et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the Hydroxychloroquine in Early Rheumatoid Arthritis (HERA) study. J Rheumatol, v. 27, p. 623-9, 2000. (Pubitemid 30151337)
69. Turesson, C.; Matteson , E. L. Genetics of rheumatoid arthritis. Mayo Clin Proc, v. 81, n. 1, p. 94-101, 2006. (Pubitemid 43054987)
70. TURESSON, C.; MATTESON, E. L. Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol, v. 21, n. 1, p. 35-40, 2009.
71. UHLIG, T. et al. Rheumatoid arthritis is milder in the new millennium: health status in RA patients 1994-2004. Ann Rheum Dis, v. 67, n. 12, p. 1710-5, 2008.
72. VAN DER CRUYSSEN, B. et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis, v. 64, n. 8, p. 1145-9, 2005.
73. VAN DER WOUDE, D. et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis, v. 69, n. 8, p. 1554-61, 2010.
74. VAN VOLLENHOVEN, R. F. Sex differences in rheumatoid arthritis: more than meets the eye. BMC Med, v. 30, n. 7, p. 12, 2009.
75. Visscher, P. M.; Hill, W. G.; WRAY, N. R. Heritability in the genomics era-concepts and misconceptions. Nat Rev Genet, v. 9, p. 255-66, 2008.
76. VOSSENAAR, E. R. et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther, v. 6, n. 2, p. R142-50, 2004a.
77. VOSSENAAR, E. R. et al. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum, v. 50, n. 11, p. 3485-94, 2004b. (Pubitemid 39488673)
78. VOSSENAAR, E. R.; VAN VENROOIJ, W. J. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther, n. 6, p. 107-11, 2004. (Pubitemid 38735665)
79. Young , A.; Koduri , G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol, v. 21, n. 5, p. 907-27, 2007. (Pubitemid 47377809)